Abstract:Abstract Hepatocellular carcinoma (HCC) is an aggressive solid tumor with vast heterogeneity in its clinical presentation and tumor biology. Genomic and transcriptomic analyses have revealed numerous HCC subtypes that are associated with patient outcome. Recently, we have identified a subset of aggressive HCC with stem cell-like traits and elevated levels of EpCAM and AFP (EpCAMhigh/AFPhigh). To identify key pathways contributing to this subset of HCCs, we used an integrated genomic strategy by comparing gene expression profiles of a well-defined HCC cohort consisting of 38 EpCAMhigh/AFPhigh and 40 EpCAM−/AFP− HCC cases using Affymetrix U133A array analyses. We identified a robust gene expression signature that can classify these two subgroups and is predictive of HCC prognosis. We validated this signature as an independent predictor of patient survival in two additional independent cohorts of HCC samples with mixed etiologies and ethnicity. Gene Set Enrichment Analysis revealed that genes containing YY1 transcriptional factor binding sites are most significantly enriched in the signature, suggesting that the YY1 signaling pathway may be functionally critical in regulating stem cell-like HCC. Genomic analysis using the Agilent 105A human arrayCGH platform revealed that the YY1 co-activator gene YY1AP1, but not YY1, is highly amplified in a majority of EpCAMhigh/AFPhigh HCCs (85%). YY1AP1 expression in HCC was significantly correlated with its genomic amplification and was also associated with patient prognosis. Using a lentiviral construct expressing YY1AP1 shRNA either constitutively or inducibly via tetracycline, we found that silencing of YY1AP1 completely blocked the growth of EpCAMhigh/AFPhigh HCC cell lines that contain YY1AP1 gene amplification. Furthermore, we found that YY1 transcriptionally activated YY1AP1-dependent EpCAM expression. In parallel, silencing of EpCAM via RNA interference also inhibited HCC cell growth. Our results suggest that YY1-YY1AP1 signaling is an oncogenic driver critical to the development of stem cell-like HCC through activation of EpCAM. Our results also demonstrate the feasibility and power of our strategy to utilize well-defined patient samples to uncover critical pathways linked to HCC subtypes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-408. doi:1538-7445.AM2012-LB-408

Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha

YY1 Promotes Colorectal Cancer Proliferation Through the Mir-526B-3p/e2f1 Axis.

Upregulation of Yin-Yang-1 Associates with Proliferation and Glutamine Metabolism in Esophageal Carcinoma

Downregulation of AZGP1 by Ikaros and Histone Deacetylase Promotes Tumor Progression Through the PTEN/Akt and CD44s Pathways in Hepatocellular Carcinoma.

Yin Yang 1 facilitates the activation, inflammation, and extracellular matrix deposition of hepatic stellate cells in hepatic fibrosis

Abstract LB-408: an Integrative Genomic Approach Uncovers Oncogenic Roles of YY1-signaling in Hepatocellular Carcinoma with Stem Cell-Like Traits

Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non‐canonical WNT pathway (FYN/STAT3)

Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review

Yin Yang-1 Suppresses Invasion and Metastasis of Pancreatic Ductal Adenocarcinoma by Downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent Mechanism

YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway

STAT5A Modulates CDYL2/SLC7A6 Pathway to Inhibit the Proliferation and Invasion of Hepatocellular Carcinoma by Targeting to Mtorc1

A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Integrative Genomics Identifies YY1AP1 As an Oncogenic Driver in EpCAM + AFP + Hepatocellular Carcinoma

Yin Yang 1 Plays an Essential Role in Breast Cancer and Negatively Regulates P27.

YY1 downregulation underlies therapeutic response to molecular targeted agents

Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma

YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study

Yin Yang 1 promotes hepatic gluconeogenesis through upregulation of glucocorticoid receptor

CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1

YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance